menu search

MLYS / Mineralys Therapeutics Builds On Phase 2 Trial Success With IPO Filing

Mineralys Therapeutics Builds On Phase 2 Trial Success With IPO Filing
Mineralys Therapeutics has filed to raise drug candidate development funding via a U.S. IPO. The firm is developing treatments for hypertension and chronic kidney disease. Read More
Posted: Jan 19 2023, 22:45
Author Name: Seeking Alpha
Views: 103045

MLYS News  

Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High?

By Zacks Investment Research
September 5, 2023

Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High?

The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 199.3% upside in the stock. While this highly sought-after met more_horizontal

Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

By Zacks Investment Research
August 22, 2023

Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Mineralys Therapeutics, Inc. (MLYS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with stro more_horizontal

Mineralys Therapeutics, Inc. (MLYS) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 12, 2023

Mineralys Therapeutics, Inc. (MLYS) Q2 2023 Earnings Call Transcript

Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2023 Results Conference Call August 7, 2023 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisor more_horizontal

Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023

By GlobeNewsWire
July 31, 2023

Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023

RADNOR, Pa., July 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on deve more_horizontal

Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023

By GlobeNewsWire
May 1, 2023

Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023

RADNOR, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on devel more_horizontal

Mineralys: New IPO And A Leader In The Hypertension Drug Development Space

By Seeking Alpha
April 21, 2023

Mineralys: New IPO And A Leader In The Hypertension Drug Development Space

Mineralys: New IPO And A Leader In The Hypertension Drug Development Space. more_horizontal

Mineralys Therapeutics sets IPO terms, which could value the HPV treatment company at nearly $600 million

By Market Watch
February 2, 2023

Mineralys Therapeutics sets IPO terms, which could value the HPV treatment company at nearly $600 million

Mineralys Therapeutics Inc. MLYS, has set terms for its initial public offering, in which the Pennsylvania-based hypertension treatment company looks more_horizontal

Hypertension Drug Maker Mineralys Therapeutics Prepares for $100 million IPO

By 24/7 Wall Street
January 19, 2023

Hypertension Drug Maker Mineralys Therapeutics Prepares for $100 million IPO

A new biopharma play is on its way as hypertension medicine developer Mineralys Therapeutics prepares to come to market. more_horizontal


Search within

Pages Search Results: